Kandzi, J. D., Englisch, A., Böer, B., Hahn, M., Wallwiener, M., Volmer, L., . . . Engler, T. (2025). Reconciling sentinel node omission with CDK4/6 inhibitor eligibility in HR+/HER2- early breast cancer: A real-world cohort analysis. Clinical breast cancer. https://doi.org/10.1016/j.clbc.2025.10.003
Chicago Style (17th ed.) CitationKandzi, Jannik Daniel, Alexander Englisch, Bettina Böer, Markus Hahn, Markus Wallwiener, Léa Volmer, Sara Brucker, Andreas Hartkopf, and Tobias Engler. "Reconciling Sentinel Node Omission with CDK4/6 Inhibitor Eligibility in HR+/HER2- Early Breast Cancer: A Real-world Cohort Analysis." Clinical Breast Cancer 2025. https://doi.org/10.1016/j.clbc.2025.10.003.
MLA (9th ed.) CitationKandzi, Jannik Daniel, et al. "Reconciling Sentinel Node Omission with CDK4/6 Inhibitor Eligibility in HR+/HER2- Early Breast Cancer: A Real-world Cohort Analysis." Clinical Breast Cancer, 2025, https://doi.org/10.1016/j.clbc.2025.10.003.